Increased Urinary Excretion of Monocyte Chemoattractant Protein-1 in Proteinuric Renal Diseases

Figures & data

Table 1. Clinical characteristics

	Non-DN group (n = 27)	DN group (n = 23)	IgAN group (n = 6)
Age (years)	61 ± 6	58 ± 9	52 ± 11
Gender (male/female)	21/6	15/8	4/2
Body mass index (kg/m^2)	23.5 ± 2.6	24.0 ± 3.1	22.8 ± 4.5
HbA1c (%)	7.2 ± 0.8	7.3 ± 1.2	4.9 ± 0.3a
Serum creatinine (mg/dL)	0.73 ± 0.14	1.48 ± 1.02b	1.33 ± 0.59c
Urinary albumin (mg/g creatinine)	9.7 (3.9–23.0)	1248.0 (312.6–4694.7)b	716.9 (290.0–2832.1)b
Urinary NAG (U/g creatinine)	4.00 (2.84–7.83)	10.99 (3.37–21.78)b	5.99 (3.26–12.01)c
Hypertention (n [%])	16 (59.3)	23 (100.0)	6 (100.0)
Hyperlipidemia (n [%])	12 (49.4)	9 (39.1)	3 (50.0)

Data are means ± SD or medians (range) or n. NAG—N-Acetylglucosaminidase.

^ap<0.05 vs. non-DN group and DN group.

^bp<0.001 vs. non-DN group.

^cp<0.05 vs. non-DN group.

Figure 1. Urinary MCP-1 excretion in type 2 diabetic patients without diabetic nephropathy (non-DN group), type 2 diabetic patients with overt diabetic nephropathy (DN group), and IgA nephropathy patients with macroalbuminuria (IgAN group).